Nektar Therapeutics (NASDAQ:NKTR) has a ROIC of -63.50% compared to its WACC of 11.16%, indicating inefficiencies in capital utilization.Comparatively, Alkermes plc (NASDAQ:ALKS) demonstrates strong financial performance with a ROIC of 18.03% and a WACC of 6.18%.Sangamo Therapeutics, Inc. (NASDAQ:SGMO) also faces challenges similar to Nektar, with a ROIC of -125.56% against a WACC of 8.02%.Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company that focuses on developing innovative medicines in are ...